Stop blaming China – they have reported 10/21 deaths in a CRISPR-TCell-PD-1 clinical trial in Jul 2018 in an American journal. Not a single citation till Nov 2019

50% of patients died in this Chinese trial :reported (Jul 2018) in an American journal

There is not a single citation of this paper in a year and half. It ticked all the boxes – CRISPR/TCells/PD-1/Immunotherapy, its should have showed up in the radar.

It now has 20/21 fatalities (reported casually on WSJ: Dec 2018 & Pulitzer: Jul 2019).

Then why was it ignored – the rush to clinical trials in the US? And India.

Printed in the “Journal of Clinical Oncology  (impact factor is a huge 26)” it noted:

1. “Mar, 2017, and Jan, 2018, we enrolled 21 patients”
2. “During the trial, 10 cancer progression related deaths occurred”

Yet, the paper concludes – “well tolerated with no unexpected safety concerns”.

Guess you need 100% fatalities for a clinical trial to be termed “unsafe” and “not well-tolerated”

“Hyperprogression % in PD-1 inhibition studies is bad (20% deaths)– adding CRISPR in that equation is lethal“. 100% is not acceptable.